{"nctId":"NCT00674362","briefTitle":"Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","startDateStruct":{"date":"2008-06"},"conditions":["Rheumatoid Arthritis"],"count":194,"armGroups":[{"label":"Certolizumab pegol 200 mg (CDP870)","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab pegol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Certolizumab pegol","otherNames":["CDP870","Cimzia"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with established diagnosis of low to moderate adult rheumatoid arthritis, currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six months and not longer than 10 years\n\nExclusion Criteria:\n\n* All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment, or with the safety of the patient\n* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial\n* Patients must not have received any previous biological therapy for rheumatoid arthritis (RA)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm). 28 joints are examined where a lower score indicates less disease activity. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"28-joint Count Disease Activity Score (DAS28-ESR) Remission (<2.6) at Both Week 20 and Week 24","description":"DAS28-ESR is calculated using the tender joint count (TJC), swollen joint count (SJC) erythrocyte sedimentation rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x Patient Global Assessment of Arthritis where 28 joints are examined and a lower score indicates less disease activity. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Simplified Disease Activity Index (SDAI) Remission (≤3.3) at Both Week 20 and Week 24","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm). 28 joints are examined where a lower score indicates less disease activity. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using Clinical Disease Activity Index (CDAI) Scores at 2 Consecutive Visits","description":"CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in cm). 28 joints are examined where a lower score indicates less disease activity. Patients losing remission (CDAI \\>2.8) for two consecutive visits will be considered as having the event on the day of the visit where remission was first lost. Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"2.83"},{"groupId":"OG001","value":"3.4","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using Simplified Disease Activity Index (SDAI) Scores at 2 Consecutive Visits","description":"SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (mg/dL), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in cm) and Physician's Global Assessment of Disease Activity (PhGADA-VAS in cm). 28 joints are examined. A lower score indicates less disease activity. Patients losing remission (SDAI \\>3.3) for two consecutive visits will be considered as having the event on the day of the visit where remission was first lost. Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"2.57"},{"groupId":"OG001","value":"2.1","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Time From Stopping Treatment (Week 24) to Loss of Remission (up to Week 52) Assessed Using DAS28-ESR Scores at 2 Consecutive Visits","description":"DAS28-ESR is calculated using tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR mm/hour) and Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS mm). 0.56x√(TJC) + 0.28x√(SJC) + 0.70xlognat(ESR) + 0.014xPtGADA-VAS. 28 joints are examined. Lower score indicates less disease activity. Patients losing remission (DAS28-ESR≥2.6) for two consecutive visits will be considered as having the event on the first of the two visits. Subjects discontinued/non-remitted by Week 24 are considered as having the event on day 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"2.96"},{"groupId":"OG001","value":"1.0","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 20% (ACR20) Response at Week 24","description":"ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 50% (ACR50) Response at Week 24","description":"ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"American College of Rheumatology 70% (ACR70) Response at Week 24","description":"ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale. Missing values were imputed using Non-Responder Imputation (NRI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24","description":"HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions). Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). Change from Baseline is computed as the value at Week 24 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.460"},{"groupId":"OG001","value":"-0.03","spread":"0.490"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Physical Component Summary (PCS) Scores at Week 24","description":"PCS norm-based scores are calculated based upon the following 8 domain scores, Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, and range from 1 to 81, where 50 represents the normative value. A larger positive value in change from Baseline indicates an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"7.50"},{"groupId":"OG001","value":"1.7","spread":"7.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Mental Component Summary (MCS) Scores at Week 24","description":"MCS norm-based scores are calculated based upon the following 8 domain scores, Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, and range from -9 to 82, where 50 represents the normative value. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"9.77"},{"groupId":"OG001","value":"0.5","spread":"9.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Physical Functioning Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"7.36"},{"groupId":"OG001","value":"0.4","spread":"8.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Role Physical Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"9.77"},{"groupId":"OG001","value":"1.7","spread":"7.81"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Bodily Pain Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"8.70"},{"groupId":"OG001","value":"2.8","spread":"8.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) General Health Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"7.59"},{"groupId":"OG001","value":"0.9","spread":"8.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Vitality Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"8.74"},{"groupId":"OG001","value":"0.6","spread":"8.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Social Functioning Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"10.21"},{"groupId":"OG001","value":"0.8","spread":"8.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Role Emotional Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"13.74"},{"groupId":"OG001","value":"-0.2","spread":"12.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36-items Health Survey (SF-36) Mental Health Domain at Week 24","description":"There are 8 SF-36 domain scores: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health, each ranging from 0 to 100, with higher scores indicating better health. A larger positive value in change from Baseline indicates an improvement","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"8.43"},{"groupId":"OG001","value":"1.2","spread":"7.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (VAS) at Week 24","description":"Change from Baseline in Patient's Assessment of Arthritis Pain-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as the value at Week 24 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"25.49"},{"groupId":"OG001","value":"1.0","spread":"24.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS) at Week 24","description":"Change from Baseline in Patient's Global Assessment of Disease Activity-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 24 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"28.69"},{"groupId":"OG001","value":"2.9","spread":"25.43"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fatigue Assessment Scale at Week 24","description":"Change from Baseline in Fatigue Assessment scale (0 to 10, 0 is \"No Fatigue\" and 10 is \"Fatigue as bad as you can imagine\") is computed as the value at Week 24 minus the Baseline value. A negative value in change from Baseline indicates an improvement. This analysis was carried out using the Last Observation Carried Forward (LOCF) method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.24"},{"groupId":"OG001","value":"0.1","spread":"2.12"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time From Stopping Treatment (Week 24) to First Flare (up to Week 52) Using Clinical Disease Activity Index (CDAI) at 2 Consecutive Visits","description":"Subjects having a flare (CDAI ≥11) between Week 24 and Week 52 for two consecutive visits will be considered as having the event on the day of the visit where flare first appeared.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":"10.28"},{"groupId":"OG001","value":"34.5","spread":"4.93"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Activity States at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for CDAI/SDAI for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Clinical Disease Activity Index (CDAI) and Disease Activity Score (DAS28-ESR) Activity States at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for CDAI/DAS28-ESR for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":null},{"groupId":"OG001","value":"0.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":null},{"groupId":"OG001","value":"0.65","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Disease Activity Score (DAS28-ESR) and Simplified Disease Activity Index (SDAI) Activity States at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for DAS28-ESR/SDAI for each category of activity (Low Disease Activity (LDA) vs. non-LDA, Medium Disease Activity (MDA) vs. non-MDA, and High Disease Activity (HDA) vs. non-HDA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":null},{"groupId":"OG001","value":"0.91","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Remission at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for CDAI/SDAI remission.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Clinical Disease Activity Index (CDAI) and Disease Activity Score (DAS28-ESR) Remission at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for CDAI/DAS28-ESR remission","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Disease Activity Score (DAS28-ESR) and Simplified Disease Activity Index (SDAI) Remission at Week 24","description":"The number representing the association is the Kappa Correlation Coefficient for DAS28-ESR/SDAI remission.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":96},"commonTop":["Nasopharyngitis","Nausea","Urinary Tract Infection","Diarrhoea","Upper Respiratory Tract Infection"]}}}